MapLight Therapeutics
Redwood City, CA · Biotechnology, Health Care, Therapeutics · 35 employees
Maplight is a biopharmaceutical company discovering and developing novel therapeutics for patients with disorders of the central nervous system (CNS).
Funding history
- Venture - Series Unknown — $188.2M — Jul 2025
- Series D — $372.5M — Jul 2025
- Venture - Series Unknown — $105.0M — Nov 2023
- Series C — $225.0M — Oct 2023
- Venture - Series Unknown — $50.0M — Jul 2023
Recent signals
- Jan 09, 2026: SEC 8-K (2.02): On January 9, 2026, MapLight Therapeutics, Inc. disclosed preliminary financial information for the fiscal year ended December 31, 2025, indicating that the Company had approximately $450 million in cash and cash equivalents. This unaudited figure is subject to change as it is a preliminary estimate based on currently available information and not final until the completion of the financial closing procedures. The event date marks the release of significant financial data relevant to investors, providing insights into the Company's liquidity position as it moves into the new fiscal year.
- Jul 28, 2025: Raised $188.2M in Venture - Series Unknown
- Jul 28, 2025: Raised $372.5M in Series D
- Mar 18, 2024: MapLight Therapeutics Appoints Vishwas Setia as Chief Financial Officer and Jonathan Gillis as Chief Administrative and Accounting Officer
- Nov 03, 2023: Raised $105.0M in Venture - Series Unknown
- Oct 30, 2023: Raised $225.0M in Series C
- Jul 19, 2023: Raised $50.0M in Venture - Series Unknown
- Nov 10, 2022: Raised $12.0M in Venture - Series Unknown
See plans & pricing → Track MapLight Therapeutics’s funding, hiring, and signals — with verified contacts — on Fundz.